Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ACC085
- Development stage
- Phase 1
- Lead developer
- AIDEA PHARMA
- Modality
- Small Molecules
- Administration
- Subcutaneous
01
Overview
ACC085 is a long-acting, small molecule non-nucleoside reverse transcriptase inhibitor (NNRTI) developed by Jiangsu Aidi Pharmaceutical for the pre-exposure prophylaxis (PrEP) of HIV-1 infection. Designed for subcutaneous administration, ACC085 aims to provide a sustained preventive solution against HIV-1 transmission, potentially offering a more convenient alternative to daily oral PrEP regimens. The drug is currently undergoing Phase 1 clinical trials in China to evaluate its safety, tolerability, pharmacokinetics, and effects on the QTc interval in healthy adults.
- Other names
- ACC085 InjectionACC-085 InjectionACC 085 Injection
02
Targets
p24 (HIV-1 capsid protein p24)Human immunodeficiency virus type 1 reverse transcriptase
Beyond the preview
Go deeper on ACC085.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ACC085.